NCT00106431 · MORE INFO

Limitations, agreements, and source contact

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) · Source last updated 2019-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Sponsor can review results at least 60 days prior to the date of submission for publication or public disclosure; sponsor will complete review within review period and will have authority to require institution/PI to delete confidential information other than the results.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: EFaust@Celgene.com
organization: Celgene Corporation
phone: 617/583-1300
title: Elizabeth Faust, PhD, Vice President, Clinical Research Services

Complete source fields

certain Agreement

other Details: Sponsor can review results at least 60 days prior to the date of submission for publication or public disclosure; sponsor will complete review within review period and will have authority to require institution/PI to delete confidential information other than the results.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: EFaust@Celgene.com
organization: Celgene Corporation
phone: 617/583-1300
title: Elizabeth Faust, PhD, Vice President, Clinical Research Services

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice